Abstract Details

Title Parkinson’s Disease, Cognition and Psychosis: Analysis of Cognition Function in People with Parkinson’s Disease with and Without Psychotic Symptoms

Topic Movement Disorders

Presentation(s) P9 - Poster Session 9 (11:45 AM-12:45 PM)

Poster/Presentation
Number 5-016

Objective

To explore cognitive function in PwPD and identify differences in PwPD with and without psychosis.

Background

Parkinson's Disease (PD) psychosis (PDP) is present in about 20% of patients with PD (PwPD). Psychosis can manifest as visual, auditory or multi-sensory illusions. Computerized cognitive testing (CCT) can identify cognitive change/impairment. Patient reported outcomes (PRO) can identify issues left unaddressed during routine care. The Scale for the Assessment of Positive Symptoms for Parkinson's Disease Psychosis (SAPS-PD) PRO is a validated measure to assess the presence of psychosis in PwPD. The relationship of cognition and PDP is not well understood. Improved recognition of PDP and treatment timing could improve clinical outcomes.

Design/Methods A retrospective cross-sectional analysis of cognitive subdomain scores was performed in PwPD who completed CCT and PRO. NeuroTrax is a CCT which objectively quantifies cognition into 7 cognitive domains (CD). T-tests assuming unequal variances (p<0.05) were utilized to evaluate the difference in SAPS-PD scores and mean scores of CDs between PwPD who experienced psychosis and those who did not. Cohen’s D analyses were performed to determine the degree of significance.

Results

255 PwPD (72± 9 years; 41.6% female) were included. A significant difference was determined across SAPS-PD and all CDs except motor function. Significant p-values and respective Cohen’s D values identified were: SAPS-PD (p=0.0000026796, d=-1.11612), Global Cognitive Score(p=0.0037699, d=0.462799252), Memory(p=0.000618214, d=0.54899), Executive Function(p=0.003161274, d=0.475634), Visual Spatial(p=0.000775034, d=0.539145), Verbal Function(p=0.00455448, d=0.46667), Attention(p=0.002395711, d=0.5058), and Information Processing Speed(p=0.036625168, d=0.398734194). Motor Function(p=0.293897605, d=0.179013) was not found to have a significant difference between groups.

Conclusions Significant differences in cognitive function were found across multiple CD. Cognitive impairment with or without psychosis can result in adverse outcomes. Improved clinician awareness and recognition of such disability in PwPD can provide opportunities for earlier intervention to avoid adverse outcomes. Phenotyping cognitive trajectories in PwPD can provide additional insight into treatment needs.

Authors/Disclosures
Kaylee A. Reilly PRESENTER	Ms. Reilly has nothing to disclose.
Logan Drucker	Mr. Drucker has nothing to disclose.
Joanna Weller (NYU Langone South Shore Neurologic Associates)	Joanna Weller has nothing to disclose.
Matthew Jo (NYU Langone)	Matthew Jo has nothing to disclose.
Nora L. Chan, MD (NYU Long Island)	Dr. Chan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for acadia.
Jennifer Vasquez, NP	Ms. Vasquez has nothing to disclose.
Myassar Zarif	Myassar Zarif has nothing to disclose.
Mark Gudesblatt, MD (South Shore Neurology Assoc. PC)	The institution of Dr. Gudesblatt has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for genentech. The institution of Dr. Gudesblatt has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen.

��ɫ��

��ɫ��